Format

Send to

Choose Destination
Alzheimers Dement. 2015 May;11(5):549-60. doi: 10.1016/j.jalz.2014.08.099. Epub 2014 Oct 1.

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.

Author information

1
Institute for Aging & Alzheimer's Disease Research and Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA. Electronic address: sid.o'bryant@unthsc.edu.
2
Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
3
Nordic Bioscience Biomarkers and Research, Neurodegenerative Diseases, Herlev, Denmark.
4
Department of Psychology, University of North Texas, Denton, TX, USA.
5
Quanterix, Inc., Lexington, MA, USA.
6
AXA Research Fund & UPMC Chair, Paris, France.
7
Department of Old Age Psychiatry, King's College London, Institute of Psychiatry, London, UK.
8
Bristol-Myers Squibb, Wallingford, CT, USA.
9
AXA Research Fund & UPMC Chair, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut dela Mémoire et de la Maladie d'Alzheimer (IM2A) & Institut du Cerveau et dela Moelle épinière (ICM), Département de Neurologie, Hôpital de laPitié- Salpétrière, Paris, France; Département de Neurologie, Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière, Paris, France.
10
Department of Pathology, University of Washington, Seattle, WA, USA.
11
Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden.
12
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
13
Alzheimer's Association, Chicago, IL, USA.
14
Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
15
Department of Neurodegeneration, Center of Neurology, Section for Dementia Research, Hertie-Institute of Clinical Brain Research, University of Tubingen, Tubingen, Germany.
16
Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
17
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
18
Department of Epidemiology, Joseph P Mailman School of Public Health, Columbia University, New York, NY, USA.
19
Alzheimer's Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA.
20
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
21
Meso Scale Discovery, Rockville, MD, USA.
22
Department of Medicine, Radiology and Psychiatry, University of California, San Francisco, CA, USA.
23
Texas Tech University Health Science Center, Garrison Institute on Aging, Lubbock, TX, USA.
24
Pfizer Inc., New York, NY, USA.

Abstract

The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross-validation across cohorts and laboratories.

KEYWORDS:

Alzheimer's disease; Biomarkers; Blood; Dementia; Diagnosis; Plasma; Serum; Treatment

PMID:
25282381
PMCID:
PMC4414664
DOI:
10.1016/j.jalz.2014.08.099
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center